N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamide and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridyl) benzenesulfonamide, and their Therapeutic use
The present invention relates generally to the field of therapeutic compounds. More particularly, for example, disorders involving inflammation and / or joint destruction and / or bone loss (e.g. diseases), disorders mediated by excessive and / or inappropriate and / or long-term activation of the immune system, inflammation And autoimmune disorders (e.g. rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), asthma, atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, multiple sclerosis, systemic (Such as lupus erythematosus, Sjogren's syndrome), rheumatoid arthritis, osteoporosis, disorders associated with bone loss such as bone loss due to osteoclast hyperactivity in cancer-related bone disease or Paget's disease, blood such as multiple myeloma, leukemia or lymphoma Malignant tumor or bladder cancer, breast cancer (female and / or male), colon cancer, renal cell cancer, kidney cancer, lung cancer, pancreatic cancer, stomach cancer, prostate cancer, brain cancer, skin Cancers such as cancer, thyroid cancer, solid tumor cancer such as basal cell enamel epithelioma or melanoma, disorders with fibrosis such as systemic sclerosis or scleroderma, or rare blood vessels such as Behcet's disease Certain substituted N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamides and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (useful in the treatment of flames 2-pyridyl) benzenesulfonamide compounds (herein collectively referred to as HMC compounds). The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds and compositions, for example in therapy. [Selection figure] None本発明は、一般に、治療用化合物の分野に関する。より詳細には、例えば、炎症及び/若しくは関節破壊及び/若しくは骨量減少を含む障害(例えば、疾患)、免疫系の過剰及び/若しくは不適切及び/若しくは長期活性化により媒介される障害、炎症及び自己免疫性障害(例えば、関節リウマチ、乾癬、乾癬性関節炎、慢性閉塞性肺疾患(COPD)、喘息、アテローム性動脈硬化、炎症性腸疾患、強直性脊椎炎、多発性硬化症、全身性エリテマトーデス、シェーグレン症候群)、関節リウマチ、骨粗鬆症、がん関連骨疾患若しくはパジェット病における破骨細胞過剰活性に伴う骨量減少などの骨量減少を伴う障害、多発性骨髄腫、白血病若しくはリンパ腫
